Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?
Agarwal, Vijay; Lind, Michael J.; Cawkwell, Lynn
Professor Michael Lind M.J.Lind@hull.ac.uk
Foundation Professor of Oncology/ Head of the Joint Centre for Cancer Studies
Dr Lynn Cawkwell L.Cawkwell@hull.ac.uk
Senior Lecturer in Cancer Genetics
The median survival for patients with malignant pleural mesothelioma remains extremely poor and there is a need for the development of more effective treatment modalities. The epidermal growth factor receptor is frequently over-expressed in malignant pleural mesothelioma samples and therefore may be a potential therapeutic target. Targeted EGFR therapy has been successful in non-small cell lung cancer using small molecule tyrosine kinase inhibitors and in colorectal cancer using monoclonal anti-EGFR antibodies. However, phase II clinical trials based on EGFR tyrosine kinase inhibitor therapy have so far not shown promise in mesothelioma. This review includes a background to targeted EGFR treatment strategies, explores putative therapy resistance mechanisms, including the role of predictive biomarkers, and describes the current status of targeted EGFR therapeutic strategies for mesothelioma patients.
|Journal Article Type||Article|
|Journal||Cancer treatment reviews|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Agarwal, V., Lind, M. J., & Cawkwell, L. (2011). Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?. Cancer Treatment Reviews, 37(7), (533-542). doi:10.1016/j.ctrv.2010.11.004. ISSN 1532-1967|
|Keywords||Oncology; Radiology Nuclear Medicine and imaging; General Medicine|
You might also like
The investigation of lipoxygenases as therapeutic targets in malignant pleural mesothelioma